KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Change in Cash (2016 - 2026)

Bristol Myers Squibb has reported Change in Cash over the past 18 years, most recently at -$635.0 million for Q1 2026.

  • Quarterly Change in Cash fell 220.27% to -$635.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.3 billion through Mar 2026, down 183.84% year-over-year, with the annual reading at -$129.0 million for FY2025, 88.99% up from the prior year.
  • Change in Cash was -$635.0 million for Q1 2026 at Bristol Myers Squibb, up from -$5.5 billion in the prior quarter.
  • Over five years, Change in Cash peaked at $4.0 billion in Q4 2023 and troughed at -$5.5 billion in Q4 2025.
  • The 5-year median for Change in Cash is -$623.0 million (2023), against an average of -$278.4 million.
  • Year-over-year, Change in Cash plummeted 2230.26% in 2022 and then surged 286.35% in 2024.
  • A 5-year view of Change in Cash shows it stood at $1.4 billion in 2022, then skyrocketed by 188.82% to $4.0 billion in 2023, then tumbled by 37.89% to $2.5 billion in 2024, then crashed by 324.45% to -$5.5 billion in 2025, then surged by 88.47% to -$635.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Change in Cash are -$635.0 million (Q1 2026), -$5.5 billion (Q4 2025), and $3.1 billion (Q3 2025).